The deal size was increased to $416.5M from $300M and priced below last closing price of $25.57. Jefferies, Goldman Sachs, Leerink, TD Cowen, Guggenheim and William Blair are acting as joint book running managers for the offering.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NAMS:
- Esperion selloff continues following competitor data from NewAmsterdam
- NewAmsterdam Pharma price target raised to $47 from $35 at Scotiabank
- NewAmsterdam Pharma announces $300M offering of ordinary shares, warrants
- NewAmsterdam Pharma price target raised to $48 from $45 at Leerink
- NewAmsterdam price target raised to $40 from $31 at RBC Capital